Trials / Completed
CompletedNCT01389206
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 797 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
Detailed description
To improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (defined as: 1) improvement of FC III or IV to FC II; 2) improvement of FC II to FC I; or 3) maintaining FC II or I)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi | observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2018-04-10
- Completion
- 2018-04-10
- First posted
- 2011-07-08
- Last updated
- 2018-08-15
Locations
76 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01389206. Inclusion in this directory is not an endorsement.